Sumitomo Pharma Co Ltd 2014 AR2
The report outlines Sumitomo Dainippon Pharma's financial and non-financial performance for fiscal 2013. Key highlights include the approval of LATUDA for bipolar depression in the United States and the establishment of Sighregen K.K. to advance the regenerative medicine and cell therapy business. The company also expanded its global pipeline in psychiatry, neurology, and oncology, while establishing a new research base in Kobe. Environmentally, the company reduced its CO2 emissions by 5.2% and waste generated by 41.0% compared to the previous fiscal year.
Company: Sumitomo Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2014
Type: AR2
Pages: 49
Sumitomo Pharma Co Ltd
Annual Report
The report outlines Sumitomo Dainippon Pharma's financial and non-financial performance for fiscal 2013. Key highlights include the approval of LATUDA for bipolar depression in the United States and the establishment of Sighregen K.K. to advance the regenerative medicine and cell therapy business. The company also expanded its global pipeline in psychiatry, neurology, and oncology, while establishing a new research base in Kobe. Environmentally, the company reduced its CO2 emissions by 5.2% and waste generated by 41.0% compared to the previous fiscal year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Apr 1, 2013 - Mar 31, 2014
Fiscal Year
2013
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Total Waste
Employees